The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients

Abstract

Although the use of combination antiretroviral therapy has resulted in spectacular improvements in morbidity and mortality of HIV-1 infected patients, a need for the development of antiretroviral compounds with new mechanisms of action remains. Maraviroc (Celsentri^®; ViiV Healthcare, Middlesex, UK) is the only drug of the class of chemokine (C-C motif) receptor 5 antagonists registered for treatment for HIV-1-infected antiretroviral therapy-experienced patients. Registration was based on the MOTIVATE-1 and -2 studies, which compared the efficacy and tolerability of maraviroc in combination with optimized background therapy with placebo. The aim of this paper is to review the MOTIVATE studies and to discuss issues related to maraviroc therapy in clinical practice such as assessment of HIV-1 coreceptor tropism.

Keywords::

• CCR5 antagonist
• maraviroc
• tropism

Financial & competing interests disclosure

SFL van Lelyveld has received financial support for research, travel, speaking engagements or consultancy from Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, Janssen-Cilag and ViiV Healthcare; AMJ Wensing from Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme, Pfizer, Janssen-Cilag, ViiV Healthcare and Virology Education; AIM Hoepelman from Bristol-Myers Squibb, Gilead, Janssen-Cilag, Merck Sharp & Dohme, Pfizer and ViiV Healthcare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.